Comment in

• Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?

  Ritchie AI, Singanayagam A.Ritchie AI, et al.Lancet. 2020 Apr 4;395(10230):1111. doi: 10.1016/S0140-6736(20)30691-7. Epub 2020 Mar 24.Lancet. 2020.PMID:32220278Free PMC article.No abstract available.
• Cytokine storms in COVID-19 cases?

  Tveito K.Tveito K.Tidsskr Nor Laegeforen. 2020 Mar 23;140. doi: 10.4045/tidsskr.20.0239. Print 2020 Mar 24.Tidsskr Nor Laegeforen. 2020.PMID:32238976English, Norwegian.No abstract available.
• Feasibility of Therapeutic Effects of the Cholinergic Anti-Inflammatory Pathway on COVID-19 Symptoms.

  Mazloom R.Mazloom R.J Neuroimmune Pharmacol. 2020 Jun;15(2):165-166. doi: 10.1007/s11481-020-09919-6. Epub 2020 May 7.J Neuroimmune Pharmacol. 2020.PMID:32378064Free PMC article.No abstract available.
• Is the HScore useful in COVID-19?

  Leverenz DL, Tarrant TK.Leverenz DL, et al.Lancet. 2020 May 16;395(10236):e83. doi: 10.1016/S0140-6736(20)31057-6. Epub 2020 May 5.Lancet. 2020.PMID:32423585Free PMC article.No abstract available.
• Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?

  Giannini M, Ohana M, Nespola B, Zanframundo G, Geny B, Meyer A.Giannini M, et al.Eur Respir J. 2020 Sep 24;56(3):2001618. doi: 10.1183/13993003.01618-2020. Print 2020 Sep.Eur Respir J. 2020.PMID:32631836Free PMC article.
• Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease.

  Schultheiß C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L, Scholz R, Wieters I, Dahlke C, Tolosa E, Sedding DG, Ciesek S, Addo M, Binder M.Schultheiß C, et al.Immunity. 2020 Aug 18;53(2):442-455.e4. doi: 10.1016/j.immuni.2020.06.024. Epub 2020 Jun 30.Immunity. 2020.PMID:32668194Free PMC article.

Dataset use reported in

• Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia.

  Sanchez-Pernaute O, Romero-Bueno FI, Selva-O'Callaghan A.Sanchez-Pernaute O, et al.Reumatol Clin (Engl Ed). 2021 Nov;17(9):556-557. doi: 10.1016/j.reumae.2020.03.005.Reumatol Clin (Engl Ed). 2021.PMID:34756322Free PMC article.No abstract available.

References

Publication types

• Letter

MeSH terms

• Antirheumatic Agents / therapeutic use
• Betacoronavirus / immunology*
• COVID-19
• COVID-19 Drug Treatment
• COVID-19 Serotherapy
• Coronavirus Infections / complications*
• Coronavirus Infections / drug therapy
• Coronavirus Infections / immunology
• Coronavirus Infections / therapy
• Cytokines / metabolism*
• Humans
• Immunization, Passive
• Immunoglobulins, Intravenous / therapeutic use
• Immunosuppression Therapy / methods*
• Immunosuppressive Agents
• Inflammation / drug therapy*
• Inflammation / etiology
• Pandemics
• Pneumonia, Viral / complications*
• Pneumonia, Viral / drug therapy
• Pneumonia, Viral / immunology
• SARS-CoV-2
• Steroids / therapeutic use

Substances

• Antirheumatic Agents
• Cytokines
• Immunoglobulins, Intravenous
• Immunosuppressive Agents
• Steroids

Grants and funding

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • ClinicalTrials.gov